At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 79 enrolled
Drug / intervention
letrozole +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Primary Hormonal Therapy for Ductal Carcinoma in Situ: Exploration of a Novel Approach to the Clinical Management of Noninvasive Breast Cancer
In Brief
A Phase 2 clinical trial evaluating letrozole, tamoxifen citrate, and 2 other interventions for Breast Cancer. Completed, enrolled 79 participants across 1 site.
Detailed Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen or letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes. PURPOSE: This clinical trial is studying how well tamoxifen or letrozole work in treating women with ductal carcinoma in situ.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsNovartis
Timeline
Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2002
First PostedFeb 2006
Primary CompletionJul 2009
Study CompletionJun 2011
TodayJul 2026
First PostedFeb 13, 2006
Enrollment StartFeb 19, 2002
Primary CompletionJul 31, 2009
Study CompletionJun 30, 2011
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 20.4 years ago
Interventions
letrozoledrug
tamoxifen citratedrug
conventional surgeryprocedure
neoadjuvant therapyprocedure